Identification of Inhibigens™ May be the Key to Successful T Cell Therapies for Solid Tumors

Time: 11:00 am
day: Conference Day 1


  • Empirical antigen selection with ATLAS™ ensures that neoantigens are both presented by the tumor and immunogenic
  • Inhibigens, also identified with ATLAS, are targets of pro-tumor responses and can be avoided in cell therapies
  • GEN-011, a peripheral blood derived, neoantigen-targeted T cell therapy is currently being evaluated in patients with solid tumors in the TITAN-1 trial (NCT04596033)